Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash from Financing Activities (2024 - 2025)

Beta Bionics (BBNX) has disclosed Cash from Financing Activities for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 98.14% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $214.9 million through Dec 2025, up 286.36% year-over-year, with the annual reading at $214.9 million for FY2025, 286.36% up from the prior year.
  • Cash from Financing Activities hit $1.1 million in Q4 2025 for Beta Bionics, down from $2.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $211.1 million in Q1 2025 to a low of -$1.2 million in Q3 2024.